120 related articles for article (PubMed ID: 8652288)
1. Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer.
Gridelli C; Perrone F; D'Aprile M; Rossi A; Palmeri S; Curcio C; Veltri E; Ianniello G; Lorusso V; Palmieri G
Eur J Cancer; 1995 Dec; 31A(13-14):2424-6. PubMed ID: 8652288
[No Abstract] [Full Text] [Related]
2. Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer.
Gridelli C; D'Aprile M; Palmeri S; Curcio C; Rossi A; Gebbia V; Veltri E; Pepe R; Pistillucci G; Bianco AR
Am J Clin Oncol; 1996 Dec; 19(6):589-91. PubMed ID: 8931678
[TBL] [Abstract][Full Text] [Related]
3. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study.
Gridelli C; Curcio C; Iaffaioli RV; Brancaccio L; D'Aprile M; Gebbia V; Rossi A; Tortoriello A; Veltri E; Maione P; Barbarisi A; Gallo C; Guida C; Perrone F
Anticancer Res; 2001; 21(6A):4179-83. PubMed ID: 11911315
[TBL] [Abstract][Full Text] [Related]
5. Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.
Tjan-Heijnen VC; Biesma B; Festen J; Splinter TA; Cox A; Wagener DJ; Postmus PE
J Clin Oncol; 1998 Aug; 16(8):2708-14. PubMed ID: 9704721
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer.
Gridelli C; Ianniello GP; Maiorino A; Curcio C; D'Aprile M; Brancaccio L; Palmeri S; Gentile M; Comella G; Pedicini T
Am J Clin Oncol; 1994 Apr; 17(2):160-2. PubMed ID: 8141108
[TBL] [Abstract][Full Text] [Related]
7. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan.
Katakami N; Takada M; Negoro S; Ota K; Fujita J; Furuse K; Ariyoshi Y; Ikegami H; Fukuoka M
Cancer; 1996 Jan; 77(1):63-70. PubMed ID: 8630941
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
[TBL] [Abstract][Full Text] [Related]
9. A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer.
Neill HB; Miller AA; Clamon GH; Perry MC; Crawford J; Green MR
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-130-S12-134. PubMed ID: 9331137
[TBL] [Abstract][Full Text] [Related]
10. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
[TBL] [Abstract][Full Text] [Related]
11. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
12. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
Pujol JL; Douillard JY; Rivière A; Quoix E; Lagrange JL; Berthaud P; Bardonnet-Comte M; Polin V; Gautier V; Milleron B; Chomy F; Chomy P; Spaeth D; Le Chevalier T
J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
[TBL] [Abstract][Full Text] [Related]
13. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy with carboplatin, etoposide and epirubicin.
Nyman CR
Thorax; 1992 Aug; 47(8):668. PubMed ID: 1329248
[No Abstract] [Full Text] [Related]
15. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
Hanauske AR; Korfel A; Perker M; Heinrich B; Schwab G; Graf M; Depenbrock H; Höffken G; Kreuser ED; Thiel E; Zwingers T; Berdel WE
Oncology; 1997; 54(5):363-70. PubMed ID: 9260596
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of combination chemotherapy with cisplatin, carboplatin and etoposide in small cell lung cancer.
Sakurai M; Ichiki M; Hayashi I
Lung Cancer; 1996 Sep; 15(2):225-32. PubMed ID: 8882989
[TBL] [Abstract][Full Text] [Related]
17. Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study.
Frasci G; Comella P; Carreca I; DeCataldis G; Muci D; Brunetti C; Russo A; Palmeri S; D'Aniello R; Giordano R; D'Aiuto M; Comella G;
Oncology; 2005; 68(2-3):223-9. PubMed ID: 16015038
[TBL] [Abstract][Full Text] [Related]
18. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
[TBL] [Abstract][Full Text] [Related]
19. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
Fukuoka M; Masuda N; Negoro S; Matsui K; Yana T; Kudoh S; Kusunoki Y; Takada M; Kawahara M; Ogawara M; Kodama N; Kubota K; Furuse K
Br J Cancer; 1997; 75(2):306-9. PubMed ID: 9010043
[TBL] [Abstract][Full Text] [Related]
20. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
Woll PJ; Hodgetts J; Lomax L; Bildet F; Cour-Chabernaud V; Thatcher N
J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
